Inactive Instrument

InventaBioTech Inc.

INVB

US46124N1037

Cyprotex plc Announces Strategic partnering deal with Cytocentrics

February 10, 2016 at 02:00 am EST

Cyprotex PLC announced the signing of a strategic partnering deal with Cytocentrics, Inc, to extend Cyprotex's capabilities in the in vitro ion channel screening market. As part of the agreement, Cytocentrics will provide equipment, cell lines, expertise and training to allow Cyprotex to provide a panel of different ion channel assays from its Watertown site, near Boston in the USA.

Latest news about InventaBioTech Inc.

InventaBiotech Inc. Announces Resignation of Keith George as Chief Financial Officer	19-10-15	CI
InventaBioTech Inc. Announces Management Changes	19-02-08	CI
InventaBioTech Inc. announced that it has received $0.3 million in funding	19-01-30	CI
WestMountain Company will Change its Name to InventaBioTech Inc	19-01-02	CI
WestMountain Company will Change its Ticker to INVB from WASM	19-01-02	CI
WestMountain Company completed the acquisition of BioDtech, Inc.	18-11-27	CI
WestMountain Company entered into a verbal agreement to acquire BioDtech, Inc.	18-11-19	CI
InventaBioTech Inc. announced that it has received $0.2 million in funding from FirstFire Capital Management LLC	18-11-07	CI
CytoBioScience, Inc. acquired WestMountain Company in a reverse merger transaction.	18-03-22	CI
CytoBioScience, Inc. announced that it has received $1.53 million in funding from BOCO Investments, LLC and another investor	18-02-28	CI
CytoBioScience, Inc. announced that it expects to receive $1.53 million in funding from BOCO Investments, LLC and another investor	18-02-25	CI
Skyline Medical Inc. (‘Skyline’) cancelled the acquisition of CytoBioScience, Inc.	17-11-06	CI
Skyline Medical Inc. signed a binding letter of intent to acquire CytoBioScience, Inc.	17-07-31	CI
CytoBioScience, Inc. announced that it has received $15.82 million in funding	16-08-09	CI
Cyprotex plc Announces Strategic partnering deal with Cytocentrics	16-02-10	CI
CytoBioScience, Inc. announced that it expects to receive $18 million in funding	15-03-10	CI

Chart InventaBioTech Inc.

Duration

Period

More charts

Company Profile

InventaBioTech, Inc., formerly WestMountain Company, is a fee-based marketing, media and investor relations consultant to public and private companies. The Company as a consultant to both public and private companies promotes public visibility and market acceptance for its clients. The Company's services include developing public recognition of the client's business plans and strategic goals, managing investor relations, and engaging in Website development and media production. The Company also utilizes various social media outlets and services to deliver the client's message. The Company's subsidiaries include WestMountain Business Consulting, Inc., WestMountain Allocation Analytics, Inc. and WestMountain Valuation Services, Inc.

Sector

Software

More about the company

Sector Other Software

	1st Jan change	Capi.
SYNOPSYS INC.	+4.28%	81.91B
CADENCE DESIGN SYSTEMS, INC.	+3.40%	76.64B
DASSAULT SYSTÈMES SE	-16.54%	52.31B
PALANTIR TECHNOLOGIES INC.	+35.85%	51.96B
ATLASSIAN CORPORATION	-22.85%	47.77B
THE TRADE DESK, INC.	+23.11%	43.3B
SEA LIMITED	+64.59%	38.29B
ROBLOX CORPORATION	-14.17%	25.1B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-9.36%	24.89B

Other Software